5
PRESCRIBING INFORMATION IS AVAILABLE ON LAST SLIDE 5 Detrusitol ® is A potent antimuscarinic 36 With balanced selectivity for both M2 and M3 receptor subtypes 35 The first antimuscarinic agent to be developed specifically for the treatment of OAB 34 Demonstrated in vivo to have greater selectivity for the bladder than other organs such as the salivary glands 37 DETRUSITOL ® XL – MODE OF ACTION 34.Van Kerrebroeck P, et al. Urology 2001;57(3):414-421. 35. Chess-Williams R. Expert Opin Ther Targets 2004;8(2):95-106. 36. Van Kerrebroeck PE, et al. Neurourol Urodyn 1998;17(5):499-512. 37. Nilvebrant L, et al. Eur J Pharmacol 1997;327(2-3):195-207. Prescribing information is available on last slide

6
PRESCRIBING INFORMATION IS AVAILABLE ON LAST SLIDE 6 The balanced receptor profile may be the reason for the proven efficacy and high tolerability of Detrusitol ® XL 35 The human detrusor muscle contains a mixture of M2 and M3 receptors in an 80:20 ratio 38 Detrusitol ® combines activity at both M2 and M3 receptors and thus may be of more benefit than agents that are selective for M3 35 Detrusitol ® XL is highly bladder-selective compared with the salivary glands, which may explain low incidence of dry mouth compared with other antimuscarinics 37 DETRUSITOL ® XL – MODE OF ACTION (CONTINUED) 35. Chess-Williams R. Expert Opin Ther Targets 2004;8(2):95-106. 37. Nilvebrant L, et al. Eur J Pharmacol 1997;327(2-3):195-207. 38. Ehlert FJ, et al. Life Sci 1997;61(18):1729-1740. Prescribing information is available on last slide

21
PRESCRIBING INFORMATION IS AVAILABLE ON LAST SLIDE 21 Prescribing information is available on last slide DETRUSITOL ® XL IN THE URGE COMPONENT OF MIXED INCONTINENCE

22
PRESCRIBING INFORMATION IS AVAILABLE ON LAST SLIDE 22 STRESS-INCONTINENCEOVERACTIVE BLADDER 49. Hunskaar S, et al. BJU Int 2004;93(3):324-330. WHAT IS MIXED INCONTINENCE? Urge to urinate but being unable to reach the toilet before leaking OR Having a strong urge to go to the toilet to urinate with no advance warning URGE INCONTINENCE (UI)SYMPTOMS 49 STRESS INCONTINENCE (SI) SYMPTOMS 49 Leak or loss of urine caused by: Sneezing Coughing Exercising Lifting Physical activity Mixed incontinence is defined as a condition where the patient experiences at least one UI and one SI symptom 49 Prescribing information is available on last slide

30
PRESCRIBING INFORMATION IS AVAILABLE ON LAST SLIDE 12-week, randomised, double-blind, placebo-controlled, multicentre study comparing efficacy and safety of Detrusitol ® XL (4mg od) with placebo in 1,015 adults with urinary frequency and urge incontinence. Primary objective of this study was to evaluate the effect of active drugs or placebo on incontinence episodes per week. Secondary objectives included evaluations of patient perceptions of urgency and frequency. VAN KERREBROECK ET AL, 2001 30 Previous slide Prescribing information is available on last slide

32
PRESCRIBING INFORMATION IS AVAILABLE ON LAST SLIDE 12 week, open label, multicentre trial to assess the speed of onset of therapeutic benefit with Detrusitol ® XL (4mg od) in 1,138 patients with OAB. Efficacy was assessed at 1, 4 and 12 weeks, measured by micturition diary and patient and physician perception of improvement. SIAMI ET AL (STAT), 2002 32 Previous slide Prescribing information is available on last slide

34
PRESCRIBING INFORMATION IS AVAILABLE ON LAST SLIDE 12-week, multinational, double-blind, placebo-controlled trial that compared the efficacy and perception of efficacy of Detrusitol ® XL (4 mg od) with placebo in terms of urinary urgency in 772 patients with OAB. The results presented are a secondary analysis from this study. FREEMAN ET AL, 2003 34 Prescribing information is available on last slide Previous slide

35
PRESCRIBING INFORMATION IS AVAILABLE ON LAST SLIDE 12-week, placebo-controlled, randomised trial comparing the effect of Detrusitol ® XL (4 mg od) with placebo in 597 patients in terms of mean urgency-free interval as recorded by use of voiding diaries. KHULLAR ET AL, 2004 35 Previous slide Prescribing information is available on last slide

36
PRESCRIBING INFORMATION IS AVAILABLE ON LAST SLIDE 9-month open-label observational study involving 3,824 patients with OAB symptoms comparing the effect of Detrusitol ® XL (4 mg od) against baseline in terms of number of urgency episodes, total urination frequency, daytime frequency, nocturia and 3 scales of OAB severity. MICHEL ET AL, 2005 36 Previous slide Prescribing information is available on last slide

37
PRESCRIBING INFORMATION IS AVAILABLE ON LAST SLIDE Post-hoc analysis of 596 patients in a 12-week, double blind, placebo-controlled trial of Detrusitol ® XL (4mg od) examining the correlation between urgency and frequency and HRQL. COYNE ET AL, 2005 37 Previous slide Prescribing information is available on last slide

38
PRESCRIBING INFORMATION IS AVAILABLE ON LAST SLIDE Pooled results from two 12-week placebo-controlled trials, involving 1,698 patients with OAB symptoms of frequency, nighttime frequency and urgency with or without incontinence, examining the efficacy of Detrusitol ® XL (4 mg od) following nighttime dosing. MATTIASSON ET AL, 2004 38 Previous slide Prescribing information is available on last slide

39
PRESCRIBING INFORMATION IS AVAILABLE ON LAST SLIDE 12-month open-label continuation trial (following on from 12-week randomised, double-blind safety and efficacy trial) involving 1,077 patients to assess the long-term safety and tolerability of Detrusitol ® XL (4 mg od) using the King’s Health Questionnaire and the SF-36 form. KELLEHER ET AL, 2002 39 Previous slide Prescribing information is available on last slide

41
PRESCRIBING INFORMATION IS AVAILABLE ON LAST SLIDE 12-month, open label, non-randomised extension study involving 759 patients who had previously received Detrusitol  XL, Detrusitol  Standard or placebo in a 12-week study. The primary objective was to assess the safety and tolerability of Detrusitol  XL 4 mg daily over a 12-month period by tracking adverse events and withdrawals. The secondary objective was to evaluate the efficacy of Detrusitol  XL 4 mg daily over the treatment period. Efficacy variables were: number of incontinence episodes per week, number of micturitions per 24 hours, volume voided per micturition and patient perception of bladder condition and urgency. KREDER ET AL, 2002 41 Prescribing information is available on last slide Previous slide

About project

Feedback

To ensure the functioning of the site, we use cookies. We share information about your activities on the site with our partners and Google partners: social networks and companies engaged in advertising and web analytics. For more information, see the Privacy Policy and Google Privacy &amp Terms.
Your consent to our cookies if you continue to use this website.